  The COVID-19 pandemic has left a significant mark on global healthcare, with
many individuals experiencing lingering symptoms long after recovering from the
acute phase of the disease, a condition often referred to as "long COVID." This
study delves into the intricate realm of immune dysregulation that ensues in
509 post-COVID-19 patients across multiple Iraqi regions during the years 2022
and 2023. Utilizing advanced machine learning techniques for immunophenotyping,
this research aims to shed light on the diverse immune dysregulation patterns
present in long COVID patients. By analyzing a comprehensive dataset
encompassing clinical, immunological, and demographic information, the study
provides valuable insights into the complex interplay of immune responses
following COVID-19 infection. The findings reveal that long COVID is associated
with a spectrum of immune dysregulation phenomena, including persistent
inflammation, altered cytokine profiles, and abnormal immune cell subsets.
These insights highlight the need for personalized interventions and tailored
treatment strategies for individuals suffering from long COVID-19. This
research represents a significant step forward in our understanding of the
post-COVID-19 immune landscape and opens new avenues for targeted therapies and
clinical management of long COVID patients. As the world grapples with the
long-term implications of the pandemic, these findings offer hope for improving
the quality of life for those affected by this enigmatic condition.
